157 related articles for article (PubMed ID: 12525759)
1. Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer.
Koizumi M; Takahashi S; Ogata E
Breast Cancer; 2003; 10(1):21-7. PubMed ID: 12525759
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
Koizumi M; Takahashi S; Ogata E
Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers of bone metabolism in breast cancer.
Lyubimova NV; Kozharskaya GV; Portnoi SM; Kushlinskii NE
Bull Exp Biol Med; 2014 Oct; 157(6):769-72. PubMed ID: 25342482
[TBL] [Abstract][Full Text] [Related]
4. The clinical use of bone resorption markers in patients with malignant bone disease.
Coleman RE
Cancer; 2002 May; 94(10):2521-33. PubMed ID: 12173317
[TBL] [Abstract][Full Text] [Related]
5. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
6. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
[TBL] [Abstract][Full Text] [Related]
7. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
[TBL] [Abstract][Full Text] [Related]
8. Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer.
Koizumi M; Matsumoto S; Takahashi S; Yamashita T; Ogata E
Clin Nucl Med; 1999 Jan; 24(1):15-20. PubMed ID: 9890487
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Body JJ; Dumon JC; Gineyts E; Delmas PD
Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
[TBL] [Abstract][Full Text] [Related]
10. Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer.
Lyubimova NV; Pashkov MV; Tyulyandin SA; Gol'dberg VE; Kushlinskii NE
Bull Exp Biol Med; 2004 Jul; 138(1):77-9. PubMed ID: 15514730
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
12. [Biomarkers of bone remodelling].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1093-100. PubMed ID: 24158641
[TBL] [Abstract][Full Text] [Related]
13. Markers of bone resorption in patients treated with pamidronate.
Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
[TBL] [Abstract][Full Text] [Related]
14. Markers of bone turnover in prostate cancer.
Garnero P
Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
[TBL] [Abstract][Full Text] [Related]
15. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Clin Orthop Relat Res; 2003 Oct; (415 Suppl):S138-47. PubMed ID: 14600604
[TBL] [Abstract][Full Text] [Related]
16. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
[TBL] [Abstract][Full Text] [Related]
17. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.
Coleman RE; Major P; Lipton A; Brown JE; Lee KA; Smith M; Saad F; Zheng M; Hei YJ; Seaman J; Cook R
J Clin Oncol; 2005 Aug; 23(22):4925-35. PubMed ID: 15983391
[TBL] [Abstract][Full Text] [Related]
19. Assessment of bone response to systemic therapy in an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European Organization for Research and Treatment of Cancer.
Vinholes J; Coleman R; Lacombe D; Rose C; Tubiana-Hulin M; Bastit P; Wildiers J; Michel J; Leonard R; Nortier J; Mignolet F; Ford J
Br J Cancer; 1999 Apr; 80(1-2):221-8. PubMed ID: 10390000
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?
Lipton A; Costa L; Coleman RE
Breast Dis; 2011; 33(2):59-69. PubMed ID: 22142664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
